Efforts to strengthen Europe as a global center for oncology clinical trials have been underway for some time, and multiple initiatives have been launched by stakeholders in recent years. At the same time, changes at the U.S. FDA and implementation of the EU Health Technology Assessment Regulation from January 2025 are bringing new considerations for sponsors deciding where to place their trial sites.
During this symposium, we will assess what progress has been achieved since the IQVIA Institute’s symposium held a year ago, examine the changes brought by the new U.S. administration, and discuss the impact of Joint Clinical Assessment requirements for all new oncology drugs submitted for registration by the EMA. We will also explore the increased use of trial sites in China and Australia.
Report reveals varied physician views on biosimilars, highlighting access gaps, low familiarity in some groups, and the need for education and policy to boost adoption, using osteoporosis as a case study.
This webinar convened global experts to explore the evolving landscape of CAR T-cell therapy and assess health system readiness across countries. Panelists shared insights on policy gaps, patient access, and cross-sector solutions to accelerate equitable delivery. The session built on findings from the IQVIA Institute’s recent report and outlined key actions to strengthen CAR T-cell therapy implementation worldwide.
Hear from the report authors as they share key findings on global medicine use and rising spending, driven by innovative therapies and widening access. This report analyzes global trends and provides insights for stakeholders through 2029.
Watch our eminent panelists share their perspectives on the impact of the IRA on oncology drug development strategy, the implications for clinical development stakeholders, and approaches to mitigating unintended consequences for innovation at the IQVIA Institute’s Pre-ASCO Symposium 2025.
Learn about spending and usage of medicines in the past year and outlook to the future, globally and across specific therapy areas and countries.
Discover trends in drug approvals and launches, pipeline activity, and data on clinical trial activity.
Examine the state of the U.S. health system, medicine usage, drug pricing, and costs for patients.
Explore research and development in oncology and the progress being made to improve representativeness of race and ethnicity in clinical trial populations.